Allergy Therapeutics (LON:AGY) Posts Quarterly Earnings Results

Allergy Therapeutics (LON:AGY) posted its quarterly earnings data on Monday. The company reported GBX (0.23) ($0.00) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Allergy Therapeutics had a negative net margin of 72.86% and a negative return on equity of 266.59%.

Allergy Therapeutics Stock Down 9.3 %

AGY stock traded down GBX 0.60 ($0.01) during midday trading on Wednesday, hitting GBX 5.85 ($0.08). The company’s stock had a trading volume of 451,067 shares, compared to its average volume of 391,161. The company’s fifty day moving average price is GBX 6.57 and its 200 day moving average price is GBX 5.92. The company has a debt-to-equity ratio of 835.48, a current ratio of 1.63 and a quick ratio of 1.48. Allergy Therapeutics has a twelve month low of GBX 2.65 ($0.03) and a twelve month high of GBX 8 ($0.10). The stock has a market capitalization of £287.53 million, a P/E ratio of -5.64, a PEG ratio of -30.70 and a beta of 1.40.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.